Introduction
============

Effective analgesia is a vital component of peri-operative care, yet survey results continue to suggest that the management of post-operative pain is often unsatisfactory ([@b2-mder-1-049]). Complications associated with moderate to severe post-operative pain are multi-systemic, and may have sequelae that by far outlast the acute peri-operative period. Intense sympathetic nervous system responses to painful stimuli will result in hypertension and may cause cardiac dysfunction or ischemia. Acute respiratory complications include hypoxia and pneumonia that may require critical care input and respiratory support. Severe or prolonged pain states trigger neurohumeral interactions that may induce neural network remodeling, promoting the development of neuropathic pain conditions or persisting complex pain syndromes ([@b19-mder-1-049]; [@b10-mder-1-049]). Non-physiological consequences of inadequately managed acute pain include restricted mobilization, which may limit the implementation of the pro-active co-ordinated multi-disciplinary approach to post-operative analgesia and ambulation that has been demonstrated to improve outcomes following major abdominal surgery ([@b11-mder-1-049]). Poor patient mobilization may also lead to delayed hospital discharge, thus limiting the throughput of surgical units and potentially impacting on healthcare budgets ([@b11-mder-1-049]).

Traditionally analgesia has been administered as intramuscular (im) or intravenous (iv) boluses of opioid analgesics. More recently, patient-controlled analgesia (PCA) systems have been established as a standard treatment for moderate to severe post-operative pain. In practice, PCA provides pain relief superior to the intermittent administration of bolus doses of opioids. Up to 30% of patients given im analgesia report severe post-operative pain, reducing to around 10% in patients treated post operatively with PCA systems ([@b9-mder-1-049]).

This article will discuss recent developments in PCA technology that may further improve post-operative analgesic therapies, namely the fentanyl iontophoretic transdermal system (ITS). This system offers a number of advantages over conventional PCA systems. The needle-free method of drug delivery avoids the risk of complications from needle-stick injuries, reduces infection risk to both patients and staff and eliminates problems relating to drug extravasation. The pre-programmed electronics eradicate the potential for potentially fatal manual programming and dosing errors. Additionally, the compact size of the system may enable greater patient mobility following surgery. The fentanyl ITS has the potential to become a valuable option in the management of acute postoperative pain.

Patient-controlled analgesia
============================

The worldwide drive to improve the treatment of post-operative pain over the last two decades has facilitated the establishment of dedicated multi-disciplinary acute pain services, supported by the development of acute pain management guidelines ([@b25-mder-1-049]). The concurrent popularization of PCA systems has resulted in marked advances in the management of acute post-operative pain ([@b20-mder-1-049]).

PCA is a well-established modality for the delivery of post-operative analgesia that has been shown to provide more effective pain relief and be preferred by patients over conventional parenteral methods of analgesic delivery ([@b9-mder-1-049]). PCA allows patients to self-administer analgesics on demand according to their personal requirements for pain relief. Compared with boluses of iv or im analgesia, the smaller but more frequent boluses of opioids via PCA systems should reduce the risks of adverse events resulting from high peak plasma opioid levels. Similarly, patients can maintain a uniform level of analgesia and avoid breakthrough pain occurring from the inevitable "analgesic gaps" resulting from delays in the administration of analgesics that are prescribed on an "as-required" basis.

However, there are drawbacks associated with the technique that may limit the extent to which it can further enhance post-operative pain management. Drug delivery is invasive, requiring a needle for administration, introducing the risks of needle-stick injury and infection to the patient and hospital personnel. Staff education and equipment maintenance is mandatory to facilitate the safe delivery of PCA. Technical aspects of the infusion device must include safety features to prevent accidental overdose or deliberate opioid diversion, such as lockable syringe covers, anti-tamper controls and dedicated infusion sets. Patient ambulation is partly restricted by the continual presence of iv lines and the infusion pump mounted on a drip-stand. Risk management standards dictate that monitoring of analgesic efficacy, physiological parameters and physical performance of the pump requires assessment by trained individuals on a regular basis.

Development of new devices
==========================

The development of novel analgesics and sophisticated delivery techniques has the potential to improve current strategies for post-operative pain management. The fentanyl hydrochloride iontophoretic transdermal system (fentanyl ITS) is a novel PCA system that has been approved in Europe and North America for the management of acute, moderate to severe post-operative pain in hospitalized patients. The fentanyl ITS is an advanced pain management system that may address many of the above concerns of safety and convenience with existing PCA modalities through the use of a pre-programmed and disposable drug delivery system. As opposed to passive transdermal fentanyl patches, the use of iontophoretic technology allows for the self-administration of a precise dose of transdermal opioid with a pharmacokinetic profile that is appropriate for acute post-operative pain management.

The transdermal route of analgesic delivery offers a number of advantages over existing strategies for the systemic administration of analgesics. The requirements for the use of needles and venous access are eliminated, making analgesic administration less invasive, simpler, and more convenient. Like other parenteral routes, drug delivery via the transdermal route also bypasses first-pass hepatic metabolism and circumvents common barriers to the use of oral analgesics immediately following surgery, such as nausea and vomiting, and difficulty swallowing. However, conventional transdermal analgesic modalities rely on passive drug diffusion creating a skin depot of active drug, from which there may be prolonged and unpredictable absorption ([@b30-mder-1-049]). Passive transdermal systems are also unable to administer individual, on-demand doses, and thus are inappropriate strategies for acute post-operative pain management.

Overview of ITS
===============

The fentanyl ITS (IONSYS™, Janssen-Cilag NV, Beerse, Belgium) has recently been approved for clinical prescription in the UK. This credit card-sized needle-free pre-programmed system may be applied to the patient's chest or upper outer arm using an adhesive that covers the bottom of the drug component housing ([Figure 1](#f1-mder-1-049){ref-type="fig"}). The patient activates the system by pressing the recessed dosing button twice within 3 seconds. Upon activation, the fentanyl ITS administers a pre-programmed 40-μg dose of fentanyl over a 10-minute period. Additional dosing requests are prevented by the system during drug delivery, thus patients may self-administer up to 6 doses per hour. The fentanyl ITS operates for up to 24 hours or a maximum of 80 doses (whichever occurs first), after which it automatically shuts down. The system may then be removed and discarded, and a new system may be applied to a different skin site if additional analgesia is required.

The entire unit is self-contained within a compact plastic housing. The dosing status of the system is indicated by a small, light-emitting diode (LED) and audible beeps. Illumination of the red LED and a single beep indicate the beginning of each dose, and the LED remains on until delivery of a dose has completed. Between doses, the system automatically communicates the approximate number of doses delivered via a series of light flashes from the LED. The total dose count may also be displayed during drug delivery by pressing the dosing button once. This device address many of the limitations with traditional PCA devices, with regards to set-up and maintenance, patient restrictions on mobilization due to the iv lines and infusion pumps, and the labor demands of the regular checking of devices. However, the demands of patient safety monitoring of physiological parameters and analgesic efficacy are unchanged. Use of this device may facilitate earlier ambulation in keeping with the enhanced recovery after surgery (ERAS) concepts.

Iontophoresis
-------------

In order to administer analgesic agents by the transdermal route, they must have certain characteristics, including a low molecular weight (\<600 Da), appropriate solubility in water and oil, an optimal partition coefficient between the membrane and the solution, and a low melting point. Fentanyl has a low molecular weight of 286 g/mol, high lipophilicity (octanol-water partition coefficient of 717), and optimal skin flux (approximately 1000 times that of morphine) ([@b13-mder-1-049]). The physicochemical characteristics of fentanyl make it not only the optimal analgesic agent for transdermal administration, but an ideal agent for iontophoretic transdermal delivery, where it has been shown that iontophoretic administration can result in circulating plasma concentrations similar to those achieved by iv infusion using a low-intensity electric current ([@b26-mder-1-049]).

The fentanyl ITS significantly enhances the rate of transdermal fentanyl delivery relative to passive diffusion. Iontophoresis is the process by which an indiscernibly low intensity electric current (170 μA) is used to drive ionized drug molecules actively by the process of electro-repulsion across the stratum corneum of the skin and into the systemic circulation. Electric current flows from the anode to the cathode, with the skin completing the circuit. Current flowing through the drug-containing anode hydrogel reservoir drives positively charged fentanyl molecules into the skin via both electro-repulsion of similarly charged molecules and bulk fluid flow resulting from electro-osmosis ([Figure 2](#f2-mder-1-049){ref-type="fig"}). The flow of electric current may also increase skin permeability, which is reversible and not indicative of skin damage ([@b8-mder-1-049]; [@b24-mder-1-049]).

Pharmacology and pharmacokinetics
---------------------------------

As the transdermal patch administers fentanyl continuously after application to the skin, it lacks the ability to deliver individual, on-demand doses. Across studies, the mean time to maximum fentanyl serum concentration (t~max~) was shown to range from 12 to 48 hours using the fentanyl patch, depending upon both the delivery rate and the duration of administration ([@b13-mder-1-049]). In contrast, a single study demonstrated that iontophoretic delivery of fentanyl using the fentanyl ITS resulted in a t~max~ of approximately 39 minutes after the completion of delivery of a single dose ([@b26-mder-1-049]). The decline in serum fentanyl concentrations following termination of treatment also occurs more rapidly with the fentanyl ITS than with the fentanyl patch, with an elimination half-life of 11 versus 13 to 25 hours ([@b13-mder-1-049]; [@b26-mder-1-049]). These data suggest that fentanyl does not accumulate in a skin depot during drug delivery by the fentanyl ITS, in contrast to the gradual release of fentanyl into the systemic circulation after cessation of treatment with the transdermal fentanyl patch.

The fentanyl ITS delivers controlled doses of fentanyl only after activation of its electronic circuitry. Minimal passive diffusion of fentanyl was found to occur from an inactivated fentanyl ITS, resulting in clinically insignificant drug absorption into the serum ([@b13-mder-1-049]). In experimental conditions, iontophoresis strongly increased transdermal permeation of the drugs as compared to passive diffusion in a charge-dependent manner. The maximal plasma concentrations were 0, 0.76 and 1.59 ng/mL with driving currents of 0, 1 and 2 mA, respectively (p = 0.010). Mean time to detection of plasma fentanyl following iontophoretic administration was 19 to 33 minutes ([@b3-mder-1-049]).

When comparing fentanyl ITS with iv administered fentanyl, serum concentrations differ significantly at 10 minutes after the initial dose is administered: 0.1 ng/mL for fentanyl ITS versus 0.7 ng/mL for iv fentanyl. However, as iontophoretic absorption increases in a time-dependent manner over the first 10 hours of dosing, the pharmacokinetic parameters of fentanyl ITS become directly comparable to those of iv fentanyl after 24 hours: maximum plasma concentrations are 1.37 and 1.82 ng/mL, time to maximum concentration 35 and 39 minutes, and area under the concentration-time curve at 24 hours 1.23 and 1.34 ng.h/mL for fentanyl ITS and intravenous fentanyl, respectively ([@b16-mder-1-049]). The mean serum terminal half-life (t~1/2~) after cessation of fentanyl ITS treatment is 11 hours, with a slope of the terminal serum concentration decline similar to that observed after iv fentanyl infusion of 13 hours ([@b26-mder-1-049]), supporting the hypothesis that fentanyl ITS drug delivery does not cause an accumulation of fentanyl in a skin depot.

The 40-μg dose of fentanyl delivered by the fentanyl ITS was selected based on the results of a dose-finding study that evaluated 3 fentanyl doses (20 μg, 40 μg and 60 μg), which found this dose to optimize analgesic efficacy with an acceptable side effect profile ([@b5-mder-1-049]). The higher dose (60 μg) increased respiratory depression, while the lower dose (20 μg) did not provide adequate analgesia.

Clinical studies have investigated the impact of various parameters on the pharmacokinetic profile of fentanyl delivered by the system. The amount of fentanyl absorbed by patients was found to be directly proportional to the magnitude of current applied by the system, with a 170 μA current producing absorption of approximately 40 μg fentanyl and a coefficient of variation similar to that of iv fentanyl infusion (22% and 23%, respectively) ([@b26-mder-1-049]). A separate study found that fentanyl absorption increases with time; in the first hour of treatment approximately 40% of each 40 μg bolus dose of fentanyl is absorbed; however after 10 hours of ITS therapy almost 100% of each 40 μg bolus is absorbed ([@b27-mder-1-049]). Although the reasons for the increase in fentanyl absorption over time are not entirely clear, it may result from the reversible alterations in the electrical conduction properties of skin that occur during exposure to electric current from the system ([@b8-mder-1-049]). Absorption of fentanyl was not affected, however, by variations in the frequency of dosing or patient characteristics, such as age, gender, ethnicity, and weight ([@b27-mder-1-049]).

Efficacy studies
================

The fentanyl ITS has been evaluated in the treatment of acute, moderate-to-severe post-operative pain in adult patients undergoing orthopedic, abdominal, or thoracic surgery in several multi-center studies with both placebo and active comparators.

Fentanyl ITS versus placebo
---------------------------

Initial assessments in a number of randomized, placebo-controlled clinical trials found the fentanyl ITS to provide pain relief superior to placebo ([@b6-mder-1-049]; [@b33-mder-1-049]). Patients were treated for up to 24 hours with the fentanyl ITS (40 μg fentanyl/10 minutes; maximum, 240 μg/hour) or a placebo system containing modified electronic circuitry to prevent iontophoretic dosing. Compared with the placebo device in almost 500 patients, 29% versus 60% of subjects reported inadequate analgesia when using fentanyl ITS. Mean pain intensity scores were lower (3.5 versus 5.4) and both patients and investigators reported the fentanyl ITS as a good or excellent method of pain control, in over 70% of cases ([@b33-mder-1-049]).

Fentanyl ITS vs transdermal fentanyl
------------------------------------

A commercially available fentanyl patch uses transdermal fentanyl delivery for the effective management of chronic pain ([@b22-mder-1-049]). The patch continuously delivers fentanyl through the skin via passive diffusion from a polymer matrix. Fentanyl delivery by the transdermal patch is characterized by a slow rate of drug absorption and sustained serum concentrations after patch removal, ideal for the management of chronic pain conditions.

Fentanyl ITS versus iv opioids
------------------------------

A prospective multi-center randomized controlled trial comparing the fentanyl ITS to iv PCA morphine in 650 patients demonstrated identical patient global assessment of pain control, with over 80% of patients reporting good or excellent pain relief in both treatment arms following major abdominal or orthopedic surgery, with similar pain intensity scores and side-effects reported in both groups ([@b12-mder-1-049]). Similar satisfaction and pain intensity score reporting was repeated in further active-comparator studies ([Table 1](#t1-mder-1-049){ref-type="table"}) ([@b32-mder-1-049]; [@b15-mder-1-049]; [@b21-mder-1-049]). There were no significant differences in the rate of withdrawal of patients from these studies due to inadequate analgesia (around 10%--15% in both iv PCA and ITS groups). It should be borne in mind that these studies were all open-label and without blinding, and as such, subject withdrawal due to patient, staff or investigator bias cannot be excluded.

Safety and tolerability
=======================

The fentanyl ITS has a favorable safety profile, particularly when considering potential programming or dosing errors. It is effectively pre-loaded with active drug, eliminating the requirement for point-of-care preparation of parenteral opioids, which has repeatedly been shown to be risk prone and has previously been a contributory factor in patient mortality, with human error accounting for around one-quarter of adverse incidents related to PCA use ([@b31-mder-1-049]; [@b7-mder-1-049]). As the fentanyl ITS is pre-programmed neither dose nor lockout period may be modified, eliminating the risk of manual errors related to dose calculations, and infusion device programming. However, these properties remove the possibility for dosing adjustments, which may be potentially limiting for patients with unique or increased opioid needs. Patient safety is further enhanced by the "lock-out" period during analgesic delivery to prevent overmedication from excessive dosing, which is, of course, a feature of all PCA systems.

Systemic complications
----------------------

Adverse events reported when using the fentanyl ITS are comparable to that of iv PCA morphine, and indeed similar to that of all opioids whichever administration route is employed ([@b32-mder-1-049], [@b33-mder-1-049]; [@b15-mder-1-049]; [@b12-mder-1-049]; [@b21-mder-1-049]). As with iv PCA morphine, nausea was the commonest reported adverse-event in around 40% to 50% of subjects in an active-comparator phase III trial ([@b29-mder-1-049]). Less frequently, vomiting, pruritis and headache have a similar reporting rate between both analgesic modalities. Adverse event data are summarized in [Table 2](#t2-mder-1-049){ref-type="table"}. Common to all systemic opioid drug prescriptions, the most potentially serious adverse event is respiratory depression, with an incidence of around 0.5% to 2% with iv PCA systems ([@b28-mder-1-049]; [@b1-mder-1-049]). While the risk must be recognized and appropriate monitoring mechanisms be in place, there were no events of clinically important respiratory depression, defined as \<8 breaths/minute for 1 minute and excessive sedation, reported in any of the 1288 patients studied during fentanyl ITS therapy ([@b7-mder-1-049]). As with all parenteral opioid administration, careful patient selection should reduce the risk of serious adverse events occurring.

Local complications
-------------------

Iontophoresis has been shown to be well tolerated by the skin, and the sensations that occur as a result of current flow have typically been minor. Application site reactions have been reported in around 20% of subjects. These were generally mild and self-limiting, including erythema and itch beneath the electrodes which needed no intervention ([@b33-mder-1-049]). It is not clear, however, how many cases may have been of a more prolonged nature. Six subjects from a total of 1288 withdrew from the four active-comparator studies due to application side reactions.

Patient perspectives
====================

The fentanyl ITS has been repeatedly shown to provide comparable post-operative analgesia with a similar adverse event profile to the accepted present standard of iv PCA morphine. It is important to note that the quality of analgesia has not been shown to be any better than PCA morphine; however, there are two key benefits worthy of discussion.

Firstly, analysis of the 'analgesic gaps' demonstrates superiority of ITS over PCA. An 'analgesic gap' is a time period where the patient requests analgesia, but for many potential reasons, analgesia is not delivered. These delays are apparent when analgesia is delivered by a nurse or physician administered bolus, and the analgesic gap exists during the time from initial perception of pain, until pain relief: during which time the staff must be alerted; perform pain assessment; prepare the appropriate analgesic to be administered (usually required two ward staff); then administer the analgesic. However, these analgesic gaps may also exist when using PCA systems. Pooled results from two of the active-comparator studies demonstrate a significantly lower rate of analgesic gaps when using ITS versus PCA (6% versus 12%), and that the median time of each gap event was shorter (15 versus 20 minutes) ([@b23-mder-1-049]). The commonest reason for an analgesic gap using the fentanyl ITS was device failure (reported in 4% subjects).

The second apparent advantage of ITS over PCA lies in the ability to ambulate patients following major surgery. National guidelines recommend that early post-operative mobilization should be an integral part of the peri-operative care package, which may facilitate reductions in the rate of post-operative thrombo-embolic events, pulmonary complications and length of in-patient stay ([@b34-mder-1-049]). Ambulation in the immediate post-operative phase requires optimization of three aspects: adequate analgesia; appropriate staff levels; freedom from connections to immobile equipment. These points have already been addressed in that fentanyl ITS has been shown to provide good or excellent analgesia in over 80% of patients, and there have been suggestions that these devices score more favorably compared to PCA and may be less demanding on labor resources from ward staff ([@b21-mder-1-049]), saving an average of 68 minutes from time of prescription to analgesic delivery compared to iv PCA ([@b4-mder-1-049]). Subjective and objective perceptions of patient mobility have been assessed in the active-comparator trials ([@b15-mder-1-049]; [@b12-mder-1-049]; [@b21-mder-1-049]) demonstrating around 95% of subjects using fentanyl ITS reporting no interference with ambulation, compared with 40% to 50% of subjects using morphine PCA apparatus.

A standard assessment tool for the utility of PCA devices in research studies is patient and investigator global assessment: in a placebo-controlled study of 484 participants, patient global assessment (PGA) rated the fentanyl ITS as excellent or good in 73%, with the study investigators' global assessment (IGA) rated the ITS as excellent or good in 72%; the system was rated as poor by PGA and IGA in 11% of uses ([@b33-mder-1-049]). In the same study, a patient satisfaction questionnaire demonstrated that the ITS was very convenient (80%) and easy to use (87%). A validated Ease of Care (EOC) questionnaire ([@b14-mder-1-049]) evaluated subjects' confidence, comfort and understanding of ITS over PCA devices in the active-comparator trials ([Table 3](#t3-mder-1-049){ref-type="table"}) ([@b15-mder-1-049]; [@b12-mder-1-049]; [@b21-mder-1-049]). Similarly, nurses and physiotherapists were asked complete EOC questionnaires to rate ITS and PCA systems with regards to time efficiency and interference with necessary activities related to patient care. On a six-point scale where 0 relates to "not at all" and 5 relates to "a great deal" with regards to time-consumption and interference with care activities, fentanyl ITS and morphine PCA respectively were rated as 0.7 vs 1.2 by nurses and 0.5 vs 0.7 by physiotherapists (p \< 0.001) ([@b12-mder-1-049]).

Values represent the mean of a score on a validated six-point scale of 0 to 5, where 0 relates to "not at all" and 5 relates to "a great deal". A higher value represents a more favorable outcome (p \< 0.05 for all values).

Alongside considerations of clinical evidence, the cost-effectiveness of medical interventions plays a sizeable role in healthcare decision-making. Cost evaluations of pain management must examine many direct and indirect expenses incurred by treatment. For example, the costs associated with iv PCA include those directly associated with the PCA pump (eg, costs related to purchase or rental, maintenance, and replacement) and consumable materials (eg, medication, iv tubing) in addition to labor costs (eg, training to use the device, set-up of the apparatus, loading of analgesic, programming the pump). The majority of the cost of treatment using the fentanyl ITS is associated with its purchase price. Labor costs would be expected to be minimal, as there is no requirement for programming or assembly of the system. Because the system is discarded after a single use, no resources would be required for maintenance or repair. While acknowledging that the pharmacoeconomics of using fentanyl ITS will be variable between different healthcare systems, it is possible to perform cost-effectiveness analysis based on current prices to the NHS in the UK. Exclusively considering raw materials, the fentanyl ITS costs around 10 times that of a standard PCA for 24 hours of therapy. However, it is difficult to specifically quantify cost savings in conjunction with potential reductions in labor intensity of ward staff and length of in-patient stay exclusively attributable to utilization of a fentanyl ITS system. One-way sensitivity analyses demonstrate very marginal financial implications of utilizing fentanyl ITS, with confidence intervals ranging between a cost saving of around £30 to a cost increment of £20 per patient use.

Conclusion
==========

Pain management is an essential element of patient care and rehabilitation following surgery, as results of clinical studies have shown that effective pain control can reduce patient morbidity and its associated healthcare costs, in addition to minimizing patient anxiety and physical discomfort. However, PCA strategies that are commonly used to treat post-operative pain introduce some risk of potentially dangerous complications resulting from use of an invasive method of drug administration and the requirement for manual programming of a PCA pump. In addition, existing PCA devices may limit patient mobility and consume substantial resources dedicated to use and maintenance of the systems.

The fentanyl ITS offers an effective and safe alternative to traditional iv PCA systems. It has been shown to be as efficacious as PCA morphine, is well tolerated by patients and has a favorable safety profile. There are few limitations associated with use of the fentanyl ITS in post-operative pain management. One potential limitation is the inability to adjust the dosing parameters, which may impact pain management in patients with considerable opioid needs. In addition, the system is associated with limitations that are common to PCA in general. Patients must be able to understand instructions for operation of the system and sufficiently alert and physically able following surgery to be suitable candidates for self-management of post-operative pain. Patients who have impaired cognitive function, or restricted mobility as a function of neuro-muscular disease, severe arthritis or site of surgery (for example, upper limb surgery) may be unable to use the fentanyl ITS, as they would with traditional iv PCA systems. The authors' experience suggests that patients studied locally have no greater difficulties activating the fentanyl ITS rather than an iv PCA handset, though at present there are no objective data to support this.

The fentanyl ITS is an advanced pain management system that may address many of the concerns of safety and convenience with existing PCA modalities through the use of a pre-programmed and disposable drug delivery system. The application of iontophoretic technology allows for non-invasive opioid analgesic delivery with a pharmacokinetic profile appropriate for the relief of acute pain in the post-operative setting.
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![The fentanyl ITS. Image shows the exterior aspect, with the on/bolus button, and the indicator LED (light emitting diode). The electrodes are visible on the interior aspect, which contacts the patient's skin), and the self-adhesive surround.](mder-1-049f1){#f1-mder-1-049}

![Iontophoretic drug delivery. Schematic diagram of iontophoretic drug delivery (Ag/AgCl electrode system). Iontophoretic devices typically utilize anodal transport, in which the ionizable drug (D^+^) and its counter-ion (A^−^) are contained within the anodal compartment, to administer therapeutics transdermally. A low-intensity electric current (e) repels ionized drug molecules (D^+^) from the anodal drug reservoir, driving them across the epidermis and into the subdermal tissue, where they are absorbed into the systemic circulation. Simultaneously, chloride ions (Cl^−^) are repelled from the cathode hydrogel reservoir. To maintain electroneutrality, oppositely charged ions, primarily Cl^−^ and Na^+^, move into the anode and cathode reservoirs, respectively. Reproduced with permission from [@b18-mder-1-049]. Iontophoretic drug delivery. *Adv Drug Deliv Rev*, 56:619--58. Copyright © 2004 Elsevier.](mder-1-049f2){#f2-mder-1-049}

###### 

Summary of efficacy data

  Author                           [@b32-mder-1-049]   [@b15-mder-1-049]                                [@b21-mder-1-049]   [@b12-mder-1-049]                                                                                           
  -------------------------------- ------------------- ------------------------------------------------ ------------------- ----------------------------------------------- ----- ----------------------------------------------- ----- -----
  Patient Global                                                                                                                                                                                                                        
  Assessment                                                                                                                                                                                                                            
   Excellent/Good                  74%                 77%                                              83%                 82%                                             85%   84%                                             86%   88%
   Fair                            12%                 13%                                              9%                  9%                                              11%   12%                                             8%    9%
   Poor                            13%                 8%                                               7%                  7%                                              4%    2%                                              4%    3%
  IGA success                      79%                 82%                                              86%                 83%                                             89%   89%                                             91%   90%
  Last mean pain intensity score   33                  31                                               3.0                 3.0                                             3.0   2.9                                             2.5   2.4
  Discontinuation                                                                                                                                                                                                                       
   Inadequate analgesia            15%                 10%[\*](#tfn2-mder-1-049){ref-type="table-fn"}   11%                 5%[\*](#tfn2-mder-1-049){ref-type="table-fn"}   9%    3%[\*](#tfn2-mder-1-049){ref-type="table-fn"}   3%    2%
   Adverse events                  6%                  6%                                               3%                  6%[\*](#tfn2-mder-1-049){ref-type="table-fn"}   6%    8%                                              3%    5%

Patient global assessment at 24 hours was the primary end-point in all four trials. [@b32-mder-1-049] reported pain intensity on a Visual Analogue Scale where 0 mm represents no pain and 100 mm represents worst possible pain. The other studies report Numerical Rating Scale (0--10) values.

p \< 0.05.

**Abbreviations:** ITS, inotophoretic transdermal system; PCA, patient-controlled analgesia.

###### 

Pooled adverse event data from active-comparator studies (Viscusi et al 2005; [@b15-mder-1-049]; [@b12-mder-1-049]; [@b21-mder-1-049])

  ------------------------------------------------------------
  Adverse event                Fentanyl ITS\   Morphine PCA\
                               n = 1288        n = 1313
  ---------------------------- --------------- ---------------
  Nausea                       39%             43%

  Application site reactions   21%             0%

  Vomiting                     12%             12%

  Pruritis                     6%              9%

  Hypotension                  3%              5%
  ------------------------------------------------------------

**Abbreviations:** ITS, inotophoretic transdermal system; PCA, patient-controlled analgesia.

###### 

Pooled mean scores from EOC questionnaires in the active-comparator trials ([@b15-mder-1-049]; [@b12-mder-1-049]; [@b21-mder-1-049])

  ---------------------------------------------------
  EOC Assessment Subscale   Fentanyl ITS\   iv PCA\
                            n = 942         n = 946
  ------------------------- --------------- ---------
  Confidence                4.51            4.15

  Movement                  4.86            3.83

  Comfort                   4.70            4.36

  Understanding             4.21            3.9
  ---------------------------------------------------

**Abbreviations:** EOC, ease of care; ITS, inotophoretic transdermal system; PCA, patient-controlled analgesia.
